Interferon News and Research

RSS

Scientists characterize type I IFN response during SARS-CoV-2 infection

In a recent study posted to the bioRxiv* preprint server, Canadian researchers assessed the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on interferon (IFN) response.

15 Jun 2022

New test can tell if you are immune to SARS-CoV-2

In a recent study published in the journal Nature Biotechnology, an international team of researchers developed and evaluated quantitative polymerase chain reaction (qPCR)-based assays to quantify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific functional T cell immunity.

15 Jun 2022

Researchers discover specific genetic signals in people who develop severe COVID-19

Researchers from the University of Sheffield and Stanford University in the US have discovered there are specific genetic signals in people who develop severe coronavirus infection.

14 Jun 2022

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

In a recent study published in the journal PNAS, researchers demonstrated higher comparative efficacy of the intranasal (IN) route of coronavirus disease 2019 (COVID-19) vaccine administration versus intramuscular route in mice.

12 Jun 2022

Study suggests the gut microbiota may be one of the factors determining the physiological inter-sex differences in pain perception

Researchers investigated whether the gut-brain axis could influence pain thresholds.

10 Jun 2022

A comparison of SARS-CoV-2 and influenza cytokine storms

In a recent study published in the Journal of Interferon & Cytokine Research, researchers compared the cytokine storms of pandemic influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

9 Jun 2022

Cognitive impairment and function in SARS-CoV-2 positive patients

Researchers assessed the association between post-acute COVID-19 cognitive impairment and kynurenine pathway activation.

9 Jun 2022

SARS-CoV-2 ORF8 protein binds to dendritic cells and induces a hyper-inflammatory cytokine storm

In a recent study posted to the bioRxiv* pre-print server, researchers examined how the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) open reading frame 8 (ORF8) protein with host dendritic cells (DCs) induced cytokine storm.

8 Jun 2022

Study on the underlying biology of long COVID

In a recent article published in the Science Translational Medicine journal, researchers analyzed prolonged and unique implications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans and hamsters following recovery.

8 Jun 2022

Persistence of viral RNA following acute infection

Professor Diane Griffin from the Johns Hopkins Bloomberg School of Public Health, USA, has recently explained the persistence mechanism of viral RNA in the human body after clinical recovery from acute infection.

6 Jun 2022

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.

6 Jun 2022

The effects of accessory protein mutations and other non-spike mutations on SARS-CoV-2 pathogenesis

Researchers looked into the role played by the accessory proteins using synthetic genomics assembly technology

2 Jun 2022

The immunogenicity and safety of the adjuvanted recombinant protein vaccine Sanofi/GSK-D614 or -B.1.351 administered as a heterologous booster dose

Researchers assessed the safety and immunogenicity of SARS-CoV-2 booster vaccines.

31 May 2022

New compounds for cancer immunotherapy via STING-mediated immune activation

Innovations in cancer immunotherapy have achieved clinical success by considerably increasing the survival rate of patients undergoing cancer treatment.

31 May 2022

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade.

30 May 2022

Study finds TGF-β2 associated with asymptomatic mild SARS-CoV-2 infection during pregnancy

A new study investigated the clinical and obstetric outcomes after SARS-CoV-2 infection in two groups of pregnant women, along with their association with the immunological parameters.

28 May 2022

Scientists unlock a new approach to kill hard-to-treat cancers

In a paper appearing in Nature today, an international group of scientists have unlocked a new way to kill hard to treat cancers. These tumors resist current immunotherapies, including those using Nobel Prize winning check-point blocking antibodies.

26 May 2022

After SARS-CoV-2 infection, anti-chemokine antibodies correlate with better outcomes

A recent study posted to the bioRxiv* preprint server illustrated that specific chemokine antibodies aid in recognizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent individuals with a desirable disease course.

26 May 2022

Immunogenicity of BNT162b2 COVID-19 vaccine in melanoma patients receiving immunotherapy

In a recent study under review at the Scientific Reports journal and posted to the Research Square* preprint server, researchers evaluated the efficacy of messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 in cancer patients under treatment with immune checkpoint inhibitors (ICIs).

25 May 2022

Vaccinated individuals with SARS-CoV-2 infection develop virus-specific T cells inside their noses

In a recent study posted to the medRxiv* preprint server, investigators in Singapore showed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection elicited broadly specific virus-selective nasal resident CD8 and CD4 T cells.

24 May 2022